#6606 MEDICATION VOLUME COMPARISON TO BIND PHOSPHATE

Abstract Background and Aims Elevated phosphate concentrations are associated with a significantly increased risk of cardiovascular disease overall mortality in patients chronic kidney disease. Current Kidney Disease: Improving Global Outcomes (KDIGO) guidelines recommend lowering elevated serum phosphorus toward the normal range end-stage on dialysis through restriction dietary intake, increase clearance by dialysis, use binders. However, ∼75% not achieving concentrations, potentially due to low adherence and/or binders’ insufficient binding capacity match intake. A binder higher could improve control clinical outcomes. This study evaluated medication volume various binders bind 1 gram phosphorus. Methods Five were assessed: ferric citrate (210 mg iron), calcium acetate (667 acetate), lanthanum carbonate (500 1,000 lanthanum), sevelamer (800 carbonate), dioxycarbonate lanthanum). The mean daily dose g was calculated as per tablet multiplied number tablets taken day. dividing its vivo capacity, based NIH DailyMed website. Results Binding required 5.6 cm3 compared (19.8 cm3), (25.0 (46.5 (73.4 cm3) (Figure 1). Conclusion found that had lowest same amount other With high dioxycarbonate, novel investigational nanotechnology product, can be welcoming choice for manage their hyperphosphatemia. drug's decreased pill size (making it easy swallow) tolerability have potential control.